Teva Pharmaceutical Industries Ltd (TEVA): Revenue
$17.26B
Year ended 2025-12-31
$17.32B
Trailing 12 months to 2026-06-30
+5.0%
3-year compound annual growth
+0.7%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $17.26B | +4.3% | 2026-02-03, From 2025-01-01 |
| 2024-12-31 | $16.54B | +4.4% | 2026-02-03, From 2024-01-01 |
| 2023-12-31 | $15.85B | +6.2% | 2026-02-03, From 2023-01-01 |
| 2022-12-31 | $14.93B | -6.0% | 2025-02-05, From 2022-01-01 |
| 2021-12-31 | $15.88B | -4.7% | 2024-02-12, From 2021-01-01 |
| 2020-12-31 | $16.66B | -1.4% | 2023-02-10, From 2020-01-01 |
| 2019-12-31 | $16.89B | -7.6% | 2022-02-09, From 2019-01-01 |
| 2018-12-31 | $18.27B | -16.4% | 2021-02-10, From 2018-01-01 |
| 2017-12-31 | $21.85B | n/c | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $21.90B | n/a | 2019-02-19, From 2016-01-07 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $17.26B | +4.3% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $14.34B | +1.0% |
| Viatris Inc (VTRS) | 2025-12-31 | $14.30B | -3.0% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $12.00B | +8.9% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $10.27B | +6.7% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $9.47B | +2.3% |
| Abbott Laboratories (ABT) | 2025-12-31 | $44.33B | +5.7% |
| Organon & Co. (OGN) | 2025-12-31 | $6.22B | -2.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $48.19B | -0.2% |
Compare TEVA, REGN, VTRS, VRTX side by side · Screen every company in Pharmaceutical Preparations ↗